Bicycle Therapeutics plc (BCYC) ADS REP 1 SHS SPON

Sell:$12.87Buy:$12.94$0.10 (0.77%)

NASDAQ:0.19%
Prices delayed by at least 15 minutes
Sell:$12.87
Buy:$12.94
Change:$0.10 (0.77%)
Deal now
Prices delayed by at least 15 minutes
Sell:$12.87
Buy:$12.94
Change:$0.10 (0.77%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.

Key people

Kevin Lee
Chief Executive Officer, Executive Director
Alethia R. Young
Chief Financial Officer, Principal Financial Officer
Alistair Milnes
Chief Operating Officer
Michael Skynner
Chief Technology Officer
Nicholas Keen
Chief Scientific Officer
Santiago Arroyo
Chief Development Officer
Nigel Crockett
Chief Business Officer
Michael Hannay
Chief Product and Supply Chain Officer
Pierre Legault
Non-Executive Chairman of the Board
Janice Bourque
Non-Executive Independent Director
Jose Carlos Gutierrez-Ramos
Non-Executive Independent Director
Richard N. Kender
Non-Executive Independent Director
Greg Winter
Non-Executive Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United Kingdom
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US0887861088
  • Market cap
    $907.96m
  • Employees
    284
  • Shares in issue
    0.00
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.